The Human Genome Project: prospects for cardiology Claude L’Enfant MD Director, National Heart, Lung, and Blood Institute National Institutes of Health,

Slides:



Advertisements
Similar presentations
Ethics of Mental Health Research. Q1: ways in which mental health differs Definition of mental illness is problematic. Terminology is very broad and inconsistent.
Advertisements

The Drug Discovery Process
1. 2 Key Applications of Genetic and Genomic Testing (slide 1 of 2) Diagnosis of Disease: Whereby genetic or genomic tests are used to screen a patient.
Examining Genetics/Genomics and Technology from a Human Rights Perspective Bonnie Holaday PhD, RN, FAAN.
1 SIMG Florence ppt The Horizons of Predictive Medicine Dr Ian Gilham Worldwide Director, Predictive Medicine Glaxo Wellcome Research and Development.
The Pursuit of Better Medicines through Genetic Research Terri Arledge, DVM US Department Head Drug Development Genetics.
Genetic Epidemiology Lecture 13 PS Timiras. A Few Definitions GENOME: THE COMPLETE SET OF GENES OF AN ORGANISM GENOTYPE: THE GENETIC CONSTITUTION OF.
Introduction to Genomics, Bioinformatics & Proteomics Brian Rybarczyk, PhD PMABS Department of Biology University of North Carolina Chapel Hill.
Hss4303b – Intro to Epidemiology March 18, 2010 – Molecular & Genetic Epidemiology.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing
Partnerships & Alliances Molecular Diagnostics Prof. K. K. Jain MD, FRACS, FFPM CEO, Jain PharmaBiotech Blaesiring 7, 4057 Basel, Switzerland Colloquim.
Thinking of Studying Biological Sciences? Dr Amrit Mudher Lecturer in Neurosciences School of Biological Sciences University of Southampton
Scientific, Economic, Social and Ethical Implications of Developing Ethnic-Specific Therapeutics, Such As BiDil The National Human Genome Center and Department.
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
Biosafety and recombinant DNA technology. Involves.... Experiments involving the construction or use of GMOs should be conducted after performing a biosafety.
Pharmacology embraces knowledge of the sources, chemical properties, biological effects and therapeutic uses of drugs. In general terms, pharmacology.
... a KAISER PERMANENTE Innovation IndiGO: Tailoring Guidelines to Individuals David M Eddy MD PhD Founder and Chief Medical Officer Emeritus Archimedes.
Georgia Wiesner, MD CREC June 20, GATACAATGCATCATATG TATCAGATGCAATATATC ATTGTATCATGTATCATG TATCATGTATCATGTATC ATGTATCATGTCTCCAGA TGCTATGGATCTTATGTA.
Clinical Research Training
Integrating Scientific Advances into Regulation: Pharmacogenomics and Pharmacogenetics Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research.
Epigenome 1. 2 Background: GWAS Genome-Wide Association Studies 3.
Genetic advances will only be acceptable if their application is carried out ethically, with due regard to autonomy, justice, education and the beliefs.
Pharmacogenomics. Developing drugs on the basis of individual genetic differences Tailoring therapies to genetically similar subpopulations results in.
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
Framingham meets genomics William P Castelli MD Director Framingham Cardiovascular Institute Adjunct-Associate Professor of Medicine Boston University.
Utilizing Science & Technology and Innovation for Development A Genome Wide Association Study for Type 2 Diabetes Susceptibility Gene and Treatment in.
The Accelerating Pace of Medical Development and Challenges in Evaluating Benefit and Risk Alasdair Breckenridge Medicines and Healthcare products Regulatory.
TOPICS IN (NANO) BIOTECHNOLOGY
Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.
A symposium presented by the IUPS Ethics Committee 37 th Congress IUPS Birmingham UK July 2013.
ELSI: Ethical, Legal and Social Issues surrounding availability of genomic information DOD and NIH devoted ~3-5% of annual HGP budgets to ELSI research.
Ownership of genetic materials, and benefits sharing (ATRIP, 4 August Session 3) Robert Kneller, J.D., M.D. Professor, Department of Intellectual Property.
Human Genome Project Daniel Ospina Joaquín Llano.
Developing medicines for the future and why it is challenging Angela Milne.
Bringing Genomics Home Your DNA: A Blueprint for Better Health Dr. Brad Popovich Chief Scientific Officer Genome British Columbia March 24, 2015 / Vancouver,
Clinical Research Informatics at the University of Michigan Daniel Clauw M.D. Professor of Medicine, Division of Rheumatology Assistant Dean for Clinical.
HUMAN GENOME PROJECT International effort of 13 years (1990 – 2003) Identified all the approximate 20,000 – 25,000 genes in human DNA Determined the sequences.
THE MURDOCK Study: A Rich Data Resource for Biomarker Discovery and Validation Brian D. Bennett 1, Jessica D. Tenenbaum 1, Victoria Christian 1, Melissa.
Biotechnology and Genomics Chapter 16. Biotechnology and Genomics 2Outline DNA Cloning  Recombinant DNA Technology ­Restriction Enzyme ­DNA Ligase 
Biotechnology AQLIMA ALI & ATIKAH MSU.
Part 1d: Exposure Assessment and Modeling Thomas Robins, MD, MPH.
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
Chapter 12 Assessment How could manipulating DNA be beneficial?
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
Consumer Advocate Perspective Clinical Trials Registration Sharon F. Terry, JAM Sharon F. Terry, JAM President and CEO, Genetic Alliance, Inc. Founding.
Ethical issues with the regulatory use of gene expression data Benjamin S Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department.
Laurie E. Locascio, Ph.D. Director, MML/NIST NIST/MML: Measurement Assurance for Biological Systems.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Ethics in Clinical Genetics and Genomics Key Knowledge Year 4 Medical Ethics and Law Thread Course, The Ethox Centre, University of Oxford.
Jan 2002 EDMA The central role of the Medical Laboratory in a World of Managed Health An EDMA presentation of the benefits of in vitro testing as a basis.
What is Biotechnology? How Long have humans used Biotechnology?
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Where Genome Meets Phenome: Rationale for Integrating.
Chapter 13 Section 13.3 The Human Genome. Genomes contain all the information needed for an organism to grow and survive The Human Genome Project (HGP)
Bringing Genomics Home Your DNA: A Blueprint for Better Health Genome British Columbia November 18, 2015 / West Vancouver, BC.
1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Moiz Bakhiet, MD, PhD, Professor and Chairman
New research areas in personalised medicines
Evidence-based Medicine
On Human Gene Editing: International Summit Statement
Genetic Testing for the Clinician
Working Groups (thematic description)
Gene Editing Tools and Methods
Integration of Genomic Medicine into Pathology Residency Training
Rossana Rivas1, Amelia Villar2, J. Tobey Clark3
Introduction to Pharmacogenetics
Stratified Medicine: Will it be the Future of Medicine?
Bringing Open Science to The Montreal Neurological Institute
Presentation transcript:

The Human Genome Project: prospects for cardiology Claude L’Enfant MD Director, National Heart, Lung, and Blood Institute National Institutes of Health, Bethesda, MD Geoffrey Pitt MD PhD Basic Life Science Research Associate Department of Molecular and Cellular Physiology Stanford University, Stanford, CA James Topper MD PhD Associate Professor of Medicine Stanford University School of Medicine Vice-President, COR Therapeutics South San Francisco, CA

The Human Genome Project brings with it the prospect for significant advances in the field of cardiology. The project will aid in: 1)the assessment of an individual’s susceptibility for disease 2)the evaluation of the progression and severity of many diseases (eg, heart failure) 3)further refinement in the field of pharmacogenetics. Relevance to cardiology?

“As public health officials we have to be careful not to oversell this advance and opportunity. It will have tremendous yield, but not for tomorrow. Nor will it be of benefit to everybody.” Claude L’Enfant MD Director, National Heart, Lung and Blood Institute National Institutes of Health Bethesda, MD Not to be oversold

The search for the genes responsible for a number of inheritable disease will be simplified. While the Human Genome Project has been center-stage, a number of other organisms, such as the mouse and Drosophila, have had, or shortly will have, their genomes sequenced. The compilation of both human and animal data will facilitate research considerably. Research implications

The particular ion channel for the T-current, targeted by the antihypertensive and anti- anginal drug mibefradil, remained unidentified until comparable genomic data from the salmon were used to identify a variety of different ion channels. The human gene corresponding to this channel has now been identified and channel function can now be studied in isolation. Practical applications Genes across species

Gene chip technology Gene chip technology, or the microarray, allows researchers studying disease models to look at the expression of multiple genes at the same time - an area of research facilitated by human genome sequencing. Image courtesy of Mitch Doktycz, Life Sciences Division, Oak Ridge National Laboratory and the Human Genome Program, U.S. Department of Energy.

The gene chip in practice Using gene chips, researchers were able to look at more than 4000 genes in a rat infarct model setting. They identified several hundred genes in 2 regions of the heart whose patterns changed dramatically in the several weeks after an infarct. Looking at the expression of multiple genes is much more powerful than studying a single gene or protein at one time. Stanton LW, Garrard LJ, Damm D, et al. Altered patterns of gene expression in response to myocardial infarction. Circ Res 2000:86;

Process of therapeutic development The first stage in therapeutic development is to identify and evaluate a target. A validated target is a gene or protein whose function, when modulated, would have a positive impact on a disease process. The second stage is to develop a therapeutic that modifies the target’s action (such as an antibody, receptor protein inhibitor, or small molecule). The third stage is to test these therapies in clinical trials, first in normal human subjects, and then in the disease state.

The major impact of the Human Genome Project in therapeutic development will be to supply an enormous array of potential targets that will require validation. A second impact of the project will be the use of genes in the natural variation of human populations to focus on potential therapeutics and clinical trials in specific risk groups (eg, hypertension). Implications for therapeutic development

“Ultimately, what we hope to do results in pharmacogenomics - and that is, we will target specific drugs to exactly the specific patients who are most likely to benefit from them.” James Topper MD PhD Associate Professor of Medicine Stanford University School of Medicine Vice-President, COR Therapeutics South San Francisco, CA Tailored therapeutics

Framingham for sale? The Framingham phenotypic data will be a valuable asset when combined with the genotypic data of the participants. The study participants are key players in the issues surrounding these decisions. This controversy highlights some of the political and social issues inherent to the Human Genome Project itself.

Framingham data Broadly applicable principles regarding ownership of the Framingham data: 1)Access to this data should be free and equal. Ownership should not be limited to one company. 2)The data should at all times remain confidential. 3)Access to the data will be decided by committee whose university faculty members must remain free from conflict of interest.

Genomics and private ownership Most genomic information should be publicly available, especially information derived from publicly funded sources. For profit biotechnology and pharmaceutical companies are uniquely suited to develop beneficial therapeutics. Such economic incentives are not necessarily present at the academic level. Intellectual property protection applies to the utility of this information if it may lead to therapeutic development.

A crucial balance Private sector Public good

Forthcoming studies A significant number of epidemiological studies are now anticipated to exploit genetic stratification and risk, as opposed to the current methods of attributing environmental risk. Many such studies looking at candidate genes derived from the human genome are expected to take place over the next 5-10 years, and will be extremely valuable.